Rechercher un médicament orphelin
Autre(s) option(s) de recherche
Autorisation de mise sur le marché sans désignation orpheline - Europe
- Nom commercial: KIOVIG
- Code ATC : J06BA02
- Identifiant UE: EU/1/05/329/...
- Date d'AMM : 19/01/2006
- Détenteur de l'AMM: BAXTER AG
- Rapport d'évaluation
Therapeutic indication
*Replacement therapy in adults, and children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production,
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed,
- Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation,
- Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).
*Immunomodulation in adults, and children and adolescents (0-18 years) in:
- Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count,
- Guillain Barré syndrome,
- Kawasaki disease,
- Multifocal Motor Neuropathy (MMN).
Liste de maladies
- Déficit immunitaire par déficit de production d'anticorps
- Maladie de Kawasaki
- Neuropathie motrice multifocale
- Syndrome d'Evans
- Syndrome de Guillain-Barré
- Thrombopénie immune